Scientists test One-Two punch against tough breast cancers
NCT ID NCT01251874
Summary
This early-stage study is testing a new combination of two drugs, veliparib and carboplatin, for people with advanced HER2-negative breast cancer that has spread. The main goals are to find the safest and most effective dose and to understand the side effects. Researchers hope the veliparib will help the carboplatin work better by stopping cancer cells from repairing themselves.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.